Skip to main content

Biopharmaceutical Aspects on the Intranasal Administration of Peptides

  • Chapter

Part of the book series: NATO ASI Series ((NSSA,volume 125))

Abstract

The intranasal route for administering peptides is probably one of the most neglected methods of delivery to the systemic circulation. Yet because of its high surface area available for absorption, its highly vasculized bed of mucosa and the fact that the nasal cavity appears to have very little metabolizing capacity all indicate that absorption across the nasal membranes is a reasonable proposition. The increasing importance which has been attached to peptides as new therapeutic agents is a consequence of the isolation and structural characterisation of various peptides, including the discovery of hypothalamic releasing hormones and pituitary hormones. The advantages of the naturally occuring peptide hormones as drug candidates have mainly been attributed to their potent pharmacological activity and their good biological tolerance. However, the disadvantages have been their broad pharmacological activity (which is often masked by a singular potent effect) and their relative short biological halflife (Table 1).

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Anik, S., McRae, G., Nerenberg, C., Worden, A., Foreman, J., JiinYu, H., Kushinsky, S., Jones, R. and Vickery, B., 1984, Nasal absorption of nasarelin acetate, the decapeptide [D-Nal(2)6] LHRH, in resus monkeys. I., J. Pharm. Sci., 73: 684.

    Article  PubMed  CAS  Google Scholar 

  • Aokif F.Y. and Crawley, J.C.W., 1976, Distribution and removal of human serum albumin — technetium 99m instilled intranasally, Br. J. Clin. Pharmacol., 3: 869.

    Article  Google Scholar 

  • Barltrop, D., 1963, Diabetes insipidus treated with synthetic lysine vasopressin, Lancet, i:27S.

    Google Scholar 

  • Bond, S.W., Hardy, J.G. and Wilson C.G., 1984, Deposition and clearance of nasal sprays, Proceedings of the Second European Congress of Biopharmaceutics and Pharmacokinetics, Salamanca, Spain, 93.

    Google Scholar 

  • Edwards, C.R.W., Kitau, M.J., Chard, T. and Besser G.M., 1973, Vasopressin analogue DDAVP in diabetes insipidus: Clinical and laboratory studies, Br. Med. J., 3: 375.

    Article  PubMed  CAS  Google Scholar 

  • Evans, W.S., Borges, L.C., Kaiser, D.L., Vance, M.L., Sellers, R.P., Macleod R.M., Vale W., Rivier, J. and Thorner, M.O., 1983, Intranasal administration of human pancreatic tumor GH-release in normal men, J. Clin. Endocr. Metab., 57: 1081.

    Article  PubMed  CAS  Google Scholar 

  • Fraser, R. and Scott, D.J., 1963, Nasal spray of synthetic vasopressin for the treatment of diabetes insipidus, Lancet, i:1159.

    Article  Google Scholar 

  • Greenwood, F.C., Hunter, W.M. and Glover, J.S., 1963, The preparation of 131I-labelled human growth hormone of high specific radioactivity, Biochem. J., 89: 114.

    PubMed  CAS  Google Scholar 

  • Hardy, J.G., Lee, S.W.S. and Wilson, C.G., 1985, intranasal drug delivery by spray and drops, J. Pharm. Pharmacol., 37: 294.

    Article  PubMed  CAS  Google Scholar 

  • Hoover, R.T., 1971, Intranasal oxytocin in eighteen hundred patients: A study on its safety as used in a community hospital, Am. J. Obstet. Gynec., 110: 778.

    Google Scholar 

  • Kobrinsky, N.L., Israels, E.D., Gerrard J.M., Cheang, M.S., Watson, C.M., Bishop, A.J. and Schroeder, M.L., 1984, Shortening of bleeding time by l-deamino-8-D-arginine vasopressin in various bleeding disorders Lancet, i:1145.

    Article  Google Scholar 

  • Lundin, S., Melin, P. and Vilhardt H., 1985, Plasma concentrations of l-deamino-8-D-arginine vasopressin after intragastric administration in the rat, Acta Endocrinol., 108: 179.

    PubMed  CAS  Google Scholar 

  • Mannucci, P.M., Canciani, M.T., Rota, L. and Donovan, B.S., 1981, Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand’s disease, Br. J. Haematol., 47: 283.

    Article  PubMed  CAS  Google Scholar 

  • Mannucci, P.M., Ruggeri, Z.M., Pareti, F.I. and Capitanio, A., 1977, l-deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand’s disease, Lancet, i:869.

    Article  Google Scholar 

  • Morimoto, K., Morisaka, K. and Kanada, A., 1985, Enhancement of nasal absorption of insulin and calciotonin using polyacrylic acid gel, J. Pharm. Pharmacol., 37: 134.

    Article  PubMed  CAS  Google Scholar 

  • Nilsson, I.M., Vilhardt, H., Holmberg, L., Åstedt, B., 1982, Association between factor VIII related antigen and plasminogen activator, Acta Med. Scand., 211: 105.

    Article  PubMed  CAS  Google Scholar 

  • Ohwaki, T., Ando, H., Watanabe, S. and Miyake, Y., 1985, Effects of Dose, pH, and Osmolarity on Nasal Absorption of Secretin in Rats, J. Pharm. Sci., 74: 550.

    Article  PubMed  CAS  Google Scholar 

  • Richardson, D.W. and Robinson A.G., 1985, Desmopressin, Ann. Int. Med., 103: 228.

    Article  PubMed  CAS  Google Scholar 

  • Rosen, S., Owaldsson, U., Blombäck, M., Larrieu, M., Nilsson I.M. and Vinazzer H., 1984, Evaluation of a chromogenic method for determining F VIII:C in hemophiliacs, von Willebrand patients and F VIII concentrate, Scand. J. Haematol., Suppl 40, 33: 93.

    Google Scholar 

  • Ruggeri, Z.M., Mannucci, P.M., Jeffcoate, S.L. and Ingram, G.I.C., 1976, Immunoradiometric assay of factor VIII related antigen, with observations in 32 patients with von Willebrand’s disease, Br. J. Haematol., 33: 221.

    Article  PubMed  CAS  Google Scholar 

  • Sandow, J. and Petri W., 1985, Intranasal administration of peptides biological activity and therapeutic efficacy, in: “Transnasal Systemic Medications,” Y.W. Chien, ed., Elsevier Science Publishers B.V., Amsterdam.

    Google Scholar 

  • Sofroniew, M.W., Madler, M., Müller, O.H. and Scriba, P.C., 1978, A method for the consistent production of high quality antisera to small peptide hormones, Fresenius Z. Anal. Chem., 290: 163.

    Article  CAS  Google Scholar 

  • Vavra, I., Machova, A., Holecek, V., Cort, J.H., Zaoral, M. and Sorm, F., 1968, Effect of a synthetic analogue of vasopressin in animals and in patients with diabetes insipidus Lancet, i:948.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Springer Science+Business Media New York

About this chapter

Cite this chapter

Harris, A.S. (1986). Biopharmaceutical Aspects on the Intranasal Administration of Peptides. In: Davis, S.S., Illum, L., Tomlinson, E. (eds) Delivery Systems for Peptide Drugs. NATO ASI Series, vol 125. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9960-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-9960-6_15

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-9962-0

  • Online ISBN: 978-1-4757-9960-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics